Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd B Sherer

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Experimental Neurology|December 31, 2002
Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregationTodd B Sherer, Jin Ho Kim, Ranjita Betarbet, et al.
Neuroscience Letters|April 11, 2003
Selective microglial activation in the rat rotenone model of Parkinson's diseaseTodd B Sherer, Ranjita Betarbet, Jin Ho Kim, et al.
Brain Pathology (Zurich, Switzerland)|November 1, 2002
Mechanistic approaches to Parkinson's disease pathogenesisRanjita Betarbet, Todd B Sherer, Donato A Di Monte, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 6, 2005
Paraquat neurotoxicity is distinct from that of MPTP and rotenoneJason R Richardson, Yu Quan, Todd B Sherer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 14, 2006
Crossroads in GDNF therapy for Parkinson's diseaseTodd B Sherer, Brian K Fiske, Clive N Svendsen, et al.
Chemical Research in Toxicology|November 16, 2004
Rotenone, deguelin, their metabolites, and the rat model of Parkinson's diseasePierluigi Caboni, Todd B Sherer, Nanjing Zhang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 11, 2014
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's diseaseWai Kin D Ko, Elsa Pioli, Qin Li, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 15, 2002
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damageTodd B Sherer, Ranjita Betarbet, Amy K Stout, et al.
Journal of Neurochemistry|January 24, 2007
Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's diseaseTodd B Sherer, Jason R Richardson, Claudia M Testa, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 3, 2003
Mechanism of toxicity in rotenone models of Parkinson's diseaseTodd B Sherer, Ranjita Betarbet, Claudia M Testa, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Experimental Neurology|December 31, 2002
Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregationTodd B Sherer, Jin Ho Kim, Ranjita Betarbet, et al.
Neuroscience Letters|April 11, 2003
Selective microglial activation in the rat rotenone model of Parkinson's diseaseTodd B Sherer, Ranjita Betarbet, Jin Ho Kim, et al.
Brain Pathology (Zurich, Switzerland)|November 1, 2002
Mechanistic approaches to Parkinson's disease pathogenesisRanjita Betarbet, Todd B Sherer, Donato A Di Monte, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 6, 2005
Paraquat neurotoxicity is distinct from that of MPTP and rotenoneJason R Richardson, Yu Quan, Todd B Sherer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 14, 2006
Crossroads in GDNF therapy for Parkinson's diseaseTodd B Sherer, Brian K Fiske, Clive N Svendsen, et al.
Chemical Research in Toxicology|November 16, 2004
Rotenone, deguelin, their metabolites, and the rat model of Parkinson's diseasePierluigi Caboni, Todd B Sherer, Nanjing Zhang, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 11, 2014
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's diseaseWai Kin D Ko, Elsa Pioli, Qin Li, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 15, 2002
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damageTodd B Sherer, Ranjita Betarbet, Amy K Stout, et al.
Journal of Neurochemistry|January 24, 2007
Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's diseaseTodd B Sherer, Jason R Richardson, Claudia M Testa, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 3, 2003
Mechanism of toxicity in rotenone models of Parkinson's diseaseTodd B Sherer, Ranjita Betarbet, Claudia M Testa, et al.
Pageof 3